Drug Trial Radar · NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.
Conditions
- Accelerated Phase Myeloproliferative Neoplasm
- Blast Phase Myeloproliferative Neoplasm
- Essential Thrombocythemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm, Not Otherwise Specified
- Polycythemia Vera
- Primary Myelofibrosis
- Secondary Myelofibrosis
Interventions
Biospecimen CollectionProcedure
Undergo buccal swab and blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration and biopsy
Bone Marrow BiopsyProcedure
Undergo bone marrow aspiration and biopsy
Decitabine and CedazuridineDrug
Given PO
IadademstatDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute leukemia response-complete (ALR-C) rateTime frame: Within 4 cycles (cycle length = 28 days)
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida · Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
UChicago Medicine Northwest Indiana
Crown Point, Indiana · Recruiting
University of Kansas Clinical Research Center
Fairway, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
NYP/Weill Cornell Medical Center
New York, New York · Recruiting
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Recruiting
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.